Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Zanger

Showing results (51-60 of 203) with videos related to

Pageof 21
Sort By:
Proteomics|April 30, 2009
Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liverElmar Langenfeld, Ulrich M Zanger, Klaus Jung, et al.
Clinical and Experimental Immunology|November 11, 1999
Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopesR Klein, U M Zanger, T Berg, et al.
Advances in Pharmacology (San Diego, Calif.)|May 27, 2018
Epigenetics and MicroRNAs in PharmacogeneticsUlrich M Zanger, Kathrin Klein, Nicole Kugler, et al.
Molecular Genetics and Genomics : MGG|November 9, 2007
Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>CAnnick Seithel, Kathrin Klein, Ulrich M Zanger, et al.
Biochemical Pharmacology|June 1, 1991
Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterizationE Jacqz-Aigrain, M Gueguen, U M Zanger, et al.
Deutsche Medizinische Wochenschrift (1946)|March 3, 2011
[Pharmacogenomics: hype or hope?]M Schwab, E Schaeffeler, U M Zanger, et al.
Epigenetics & Chromatin|April 23, 2015
Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintainedGoran Kungulovski, Suneetha Nunna, Maria Thomas, et al.
Frontiers in Pharmacology|August 20, 2011
Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone HydrolysisStephan Riedmaier, Kathrin Klein, Stefan Winter, et al.
ALTEX|August 30, 2003
V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humansNiels Krebsfaenger, Thomas E Mürdter, Ulrich M Zanger, et al.
Pharmacogenetics and Genomics|September 27, 2006
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6Claudia Toscano, Sebastian Raimundo, Kathrin Klein, et al.
Pageof 21

Showing results (51-60 of 203) with videos related to

Sort By:
Pageof 21
Proteomics|April 30, 2009
Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liverElmar Langenfeld, Ulrich M Zanger, Klaus Jung, et al.
Clinical and Experimental Immunology|November 11, 1999
Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopesR Klein, U M Zanger, T Berg, et al.
Advances in Pharmacology (San Diego, Calif.)|May 27, 2018
Epigenetics and MicroRNAs in PharmacogeneticsUlrich M Zanger, Kathrin Klein, Nicole Kugler, et al.
Molecular Genetics and Genomics : MGG|November 9, 2007
Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>CAnnick Seithel, Kathrin Klein, Ulrich M Zanger, et al.
Biochemical Pharmacology|June 1, 1991
Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterizationE Jacqz-Aigrain, M Gueguen, U M Zanger, et al.
Deutsche Medizinische Wochenschrift (1946)|March 3, 2011
[Pharmacogenomics: hype or hope?]M Schwab, E Schaeffeler, U M Zanger, et al.
Epigenetics & Chromatin|April 23, 2015
Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintainedGoran Kungulovski, Suneetha Nunna, Maria Thomas, et al.
Frontiers in Pharmacology|August 20, 2011
Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone HydrolysisStephan Riedmaier, Kathrin Klein, Stefan Winter, et al.
ALTEX|August 30, 2003
V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humansNiels Krebsfaenger, Thomas E Mürdter, Ulrich M Zanger, et al.
Pharmacogenetics and Genomics|September 27, 2006
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6Claudia Toscano, Sebastian Raimundo, Kathrin Klein, et al.
Pageof 21